Abstracts significantly more likely to experience an ER visit or an inpatient stay compared to patients in capitated plans (odds ratio for ER visit: 1.64, p < 0.05; odds ratio for an inpatient stay: 1.11, p < 0.05). CONCLUSIONS: The results of this study confirm that utilization rates are higher in FFS plans; however, the strength of the association was not as robust when the regression models were adjusted for propensity score. Capitated plans seek to reduce resource utilization.
PDB64 USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES
Pinto S, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: Prevention or mediation of adverse events can significantly impact a patient's quality of life and their employer's health care costs. Decision modeling can be utilized to map pharmacists interventions provided through an employee-sponsored medication therapy management (MTM) program and calculate consequent cost savings associated with improved clinical outcomes. METHODS: A total of 700 employees from 2 employer groups participate in a pharmacist provided MTM program. A team of clinicians and researchers classified and created codes for specific pharmacist interventions, resultant physician and/or patient responses, and consequent outcomes. Data was extracted from patient charts and entered into Microsoft Excel. Costs associated with each decision outcome were calculated from claims data. A one-year decision-analytic model was constructed using TreeAge Pro Suite 2008 to identify the cost savings per intervention. RESULTS: A total of 218 interventions were made by the pharmacists. The most frequently used interventions were "explained and advised the use of pattern management" (N = 95, 43.4%) and "alerted the physician of an abnormal A1c level" (N = 64, 29.2%). Cost savings resulting from diabetic interventions for ER visits ($71.00 -$337 PPPY), inpatient hospitalization ($460.00 -$2360.00 PPPY), and total costs ($26.00 -$274.00 PPPY). All but one intervention resulted in a loss of cost savings for office visits, indicating that patients visited specialty physicians more often after beginning the program. The total cost savings for these interventions were $165.00 PPPY and $145.00 PPPY, respectively. CONCLU-SIONS: This decision-analytic model can be used as a rubric for providers seeking the most effective interventions to utilize for MTM programs, thereby reducing trial-anderror and diminishing health care costs. The model illustrates the potential return on investment the employer realized as a result of sponsoring employee participation in this program.
PDB65 IMPROVED PATIENT OUTCOMES RESULTING FROM PHYSICIANS' THERAPY DECISIONS BASED ON PHARMACISTS' RECOMMENDATIONS
Pinto S, Blazejewski L, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: Literature suggests that while pharmacists may be viewed as the most trusted health care professionals by patients, other health care professionals may often fail to trust them with making decisions regarding drug therapy regimens. Limited information is available regarding physicians' therapy decisions based on pharmacist's recommendations and the resulting patient clinical outcomes. This study aimed at finding if physicians' therapy decisions based on pharmacist's recommendations lead to optimal patient outcomes. METHODS: Approximately 700 employees from 2 employer groups have participated in an employer-supported pharmacist provided disease state management program. The program is provided at seven independent pharmacies across Northwest Ohio. A team of clinical pharmacists and researchers classified and created codes for specific pharmacist-provided interventions, resultant physician and/or patient responses, and consequent outcomes. Data was extracted from patient charts and entered into Microsoft Excel. Frequencies and percentages of pharmacists' interventions, physicians' responses and outcomes were calculated using SPSS ver. 17.0. A decision tree was created using TreeAge Pro Suite 2008 to map interventions to responses to improved/unimproved outcomes. RESULTS: A total of 446 pharmacist interventions with corresponding physician responses and patient outcomes were made. The most frequent interventions involved drug therapy (N = 138, 31%) and formulary management (N = 105, 23.5%). The most frequent responses by physicians were "physician acknowledged recommendation, monitoring added" (N = 58, 13%) and "physician added a medication" (N = 51, 11.4%). Physicians responded favorably to the pharmacists' interventions 54.1% of the time. When physicians responded favorably, an improvement was seen in 91.2% of patient outcomes compared to only 64% when physicians declined or did not respond to pharmacists' interventions. CONCLUSIONS: Positive health outcomes result from therapy decisions made by physicians following pharmacists' recommendations. In an effort to save costs and improve care, pharmacist-physician collaboration is essential. were used in the RADAR tool to assess the yearly rate of glycosylated hemoglobin (HbA1c) testing and low-density lipoprotein-cholesterol (LDL-C) screening. Other HEDIS comprehensive diabetes care-related measures reported by the RADAR tool included the rate of patients with (a) hypertension; (b) nephropathy; and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical utilization patterns along with medication adherence were also reported. RESULTS: A total of 287,195 patients with diabetes were identified, with 92% of the patients identified as having type 2 diabetes. Mean age of the patients was 53 years, and 52% were male. Over 70% of the patients with diabetes had cardiovascular risk factors such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropathy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes patients received HbA1c testing, while 71% of the patients received LDL-C screening within one year. Testing within one year was less than the national HEDIS Medicaid 25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes care measures in the i3 Innovus database. CONCLUSIONS: In this population, LDL-C screenings within one year for diabetes patients were above the national HEDIS lowperformance level, while HbA1c testing within one year for diabetes patients was below the low-performance level, utilizing the RADAR tool for analyses. These findings indicate an opportunity for improvement.
PDB66 EVALUATION OF SELECTED COMPREHENSIVE DIABETES CARE MEASURES IN A MANAGED CARE DATABASE BY USING THE RETROSPECTIVE ANALYSIS FOR DIABETES ACTION AND REPORTING TOOL

PDB67 ECONOMIC EVALUATION OF TYPE 2 DIABETES -IMPACT OF PRICING AND REIMBURSEMENT REFORMS
Ilavska A 1 , Glatz P 2 , Hloska A 3 , Filko M 4 1 Medispektrum, Bratislava, Slovak Republic, 2 Janssen-Cilag, Bratislava, Slovak Republic, 3 Ministry of Health, Bratislava, Slovak Republic, 4 Ministry of Finance, Bratislava, Slovak Republic OBJECTIVES: Type 2 diabetes mellitus is serious condition associated of chronic complications whose economic impact on both patients and society is constantly increasing. Diabetics are the 4st in the drug spending in Slovakia. Our objectives was to explore drug costs for diabetes and besides the costs to explore also drug consumption and number treated patients with antidiabetics. METHODS: The data on drugs consumption were from national databases IMS Health and Pharmadata Ltd. 
